Knight Therapeutics, Inc. (GUD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BioSyent, Inc.

Knight Therapeutics, Inc.

HLS Therapeutics, Inc.

InnoCan Pharma Corp.

Fennec Pharmaceuticals, Inc.

Ayr Wellness, Inc.

NervGen Pharma Corp.

Arch Biopartners, Inc.

Defence Therapeutics Inc

Cybin, Inc.

Mindset Pharma, Inc.

Why is Knight Therapeutics, Inc. ?

With a fall in PBT of -809.79%, the company declared Very Negative results in Jun 25

INTEREST(Q) At CAD 2.37 MM has Grown at 35.19%
RAW MATERIAL COST(Y) Grown by 15.29% (YoY)
CASH AND EQV(HY) Lowest at CAD 232.7 MM

Underperformed the market in the last 1 year

The stock has generated a return of 3.05% in the last 1 year, much lower than market (S&P/TSX 60) returns of 22.54%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Knight Therapeutics, Inc. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Knight Therapeutics, Inc.

13.3%

0.18

26.07%

S&P/TSX 60

20.39%

1.54

14.62%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

22.33%

EBIT Growth (5y)

-1.70%

EBIT to Interest (avg)

-1.52

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

0.41

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.15%

ROCE (avg)

0.11%

ROE (avg)

1.02%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.75

EV to EBIT

-65.07

EV to EBITDA

13.85

EV to Capital Employed

0.75

EV to Sales

1.52

PEG Ratio

Dividend Yield

ROCE (Latest)

-1.16%

ROE (Latest)

-0.11%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

DEBTORS TURNOVER RATIO(HY)

Highest at 3.8%

NET SALES(Q)

Highest at CAD 107.36 MM

-23What is not working for the Company

INTEREST(Q)

At CAD 2.37 MM has Grown at 35.19%

RAW MATERIAL COST(Y)

Grown by 15.29% (YoY

CASH AND EQV(HY)

Lowest at CAD 232.7 MM

DEBT-EQUITY RATIO (HY)

Highest at 1.78 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.07%

PRE-TAX PROFIT(Q)

Lowest at CAD -9.87 MM

NET PROFIT(Q)

Lowest at CAD -6.88 MM

EPS(Q)

Lowest at CAD -0.13

Here's what is working for Knight Therapeutics, Inc.

Net Sales

Highest at CAD 107.36 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Debtors Turnover Ratio

Highest at 3.8%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Knight Therapeutics, Inc.

Pre-Tax Profit

At CAD -9.87 MM has Fallen at -904.32%

over average net sales of the previous four periods of CAD 1.23 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CAD MM)

Net Profit

At CAD -6.88 MM has Fallen at -1,311.09%

over average net sales of the previous four periods of CAD 0.57 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CAD MM)

Interest

At CAD 2.37 MM has Grown at 35.19%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)

Pre-Tax Profit

Lowest at CAD -9.87 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CAD MM)

Net Profit

Lowest at CAD -6.88 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CAD MM)

EPS

Lowest at CAD -0.13

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CAD)

Cash and Eqv

Lowest at CAD 232.7 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 1.78 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 2.07%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost

Grown by 15.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales